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Background: Differences in DNAmethylation have been reported in B and T lymphocyte
populations, including CD4+ T cells, isolated from rheumatoid arthritis (RA) patients
when compared to healthy controls. CD4+ T cells are a heterogeneous cell type
with subpopulations displaying distinct DNA methylation patterns. In this study, we
investigated DNA methylation using reduced representation bisulfite sequencing in
two CD4+ T cell populations (CD4+ memory and naïve cells) in three groups: newly
diagnosed, disease modifying antirheumatic drugs (DMARD) naïve RA patients (N = 11),
methotrexate (MTX) treated RA patients (N = 18), and healthy controls (N = 9) matched
for age, gender and smoking status.
Results: Analyses of these data revealed significantly more differentially methylated
positions (DMPs) in CD4+ memory than in CD4+ naïve T cells (904 vs. 19 DMPs) in RA
patients compared to controls. The majority of DMPs (72%) identified in newly diagnosed
and DMARD naïve RA patients with active disease showed increased DNA methylation
(39 DMPs), whereas most DMPs (80%) identified in the MTX treated RA patients in
remission displayed decreased DNAmethylation (694 DMPs). Interestingly, we also found
that about one third of the 101 known RA risk loci overlapped (±500 kb) with the DMPs.
Notably, introns of the UBASH3A gene harbor both the lead RA risk SNP and two DMPs
in CD4+ memory T cells.
Conclusion: Our results suggest that RA associated DNA methylation differences vary
between the two T cell subsets, but are also influenced by RA characteristics such as
disease activity, disease duration and/or MTX treatment.
Keywords: rheumatoid arthritis, T cells, CD4 memory, CD4 naïve, DNA methylation, RRBS, epigenetic,
methotrexate
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease that
causes pain and swelling of multiple joints in the body. The
underlying disease mechanisms are believed to involve a complex
interplay between common genetic and environmental factors.
The heritability of RA has been estimated to be ∼50% for anti-
citrullinated protein antibody (ACPA) positive RA and ∼20%
for ACPA negative RA in a large familial aggregation study (1).
Genome-wide association studies (GWAS) have identified more
than 100 RA risk loci, mostly conferring risk to ACPA positive
RA, marked by lead single nucleotide polymorphisms (SNPs)
across various populations (2). The risk SNPs have small effect
sizes, and only explain parts of heritability in RA. Environmental
and epigenetic factors are also thought to be involved in the RA
disease pathogenesis (3) of which smoking is the only established
environmental risk factor (4, 5).
Epigenetic modifications are important for regulation and
maintenance of cell type specific biological functions, and
alterations in the epigenome have been found to be associated
with RA (6). Themost studied epigeneticmodification in humans
is DNAmethylation of cytosine followed by a guanine at so-called
CpG sites (CpGs). CpGs are often clustered in regions called
CpG islands (CGIs), which frequently overlap gene promoters
(7). DNA methylation in promotor regions is usually negatively
correlated with transcription of the nearby gene (8).
A wide range of immune cells has been implicated in
the pathogenesis of RA. One of the most widely used drugs
for treatment of RA, methotrexate (MTX) (9), acts as an
immunosuppressant in proliferating cells (10), and of these,
the most relevant cell population for RA is CD4+ T cells
(11). Interestingly, the RA risk loci are enriched in accessible
chromatin regions (H3K4me3 peaks) in T cells, including both
CD4+ naïve and CD4+ memory T cells (2). Studies have
identified cell type specific DNA methylation differences in B
(CD19+) and T (CD3+) lymphocytes (12, 13), as well as CD4+
T cells subsets (14, 15) isolated from RA patients compared to
healthy controls.
However, memory and naïve CD4+ T cells also display
distinct genome-wide and gene-specific DNA methylation
patterns as a result of normal differentiation (16); hence analyses
of bulk T cells may be confounded by different proportions of
naïve and memory T cells. Given the recent observations that
CD4+ T cell subset distributions are abnormal both in treatment
naïve RA patients and in RA patients who has undergone MTX
Abbreviations: ACPA, Anti-citrullinated protein antibody; ACR, American
College of Rheumatology; ARCTIC REWIND, The Assessing Withdrawal
of Disease-Modifying Anti-rheumatic Drugs in Rheumatoid Arthritis; CGIs,
CpG islands; CpGs, CpG sites; CRP, C-reactive protein; DAS28, Disease
activity score 28; DMARD, Disease modifying antirheumatic drugs; DMPs,
Differentially methylated positions; ESR, Erythrocyte sedimentation rate;
EULAR, European League Against Rheumatism; FDR, False discovery rate;
GO, Gene ontology; GWAS, Genome-wide association studies;
mRRBS, Multiplexed reduced representation bisulfite sequencing; MTX,
Methotrexatel; NOR-VEAC, The Norwegian Very Early Arthritis Clinic; RA,
Rheumatoid arthritis; RF, Rheumatoid factor; SD, Standard deviation; SNPs,
Single nucleotide polymorphisms.
treatment (17) methylation profiles for distinct CD4+ T cell
subpopulations should be investigated separately.
Methylation levels have so far only been assessed by array-
based methods in RA, however reduced representation bisulfite
sequencing (RRBS) using next generation sequencers allows
for an interrogation of even more CpG sites. RRBS enriches
for CpG dinucleotides by utilizes the restriction enzyme MspI
(C∧CGG) to digest the DNA sample before bisulfite conversion
and sequencing.
In this study, we aimed to investigate whether we could detect
DNA methylation differences in primary naïve and memory
CD4+ T cells from RA patients. To do this, we conducted an
epigenome-wide association study using RRBS on isolated T cell
populations from two different RA cohorts; (1) disease modifying
anti-rheumatic drug (DMARD) naïve RA patients with active
disease and (2) MTX-treated RA patients who had been in
remission for >12 months. The two cohorts were compared to
matched healthy controls.
MATERIALS AND METHODS
Subjects
A total of 29 RA patients diagnosed according to the 2010
American College of Rheumatology/European League Against
Rheumatism (ACR/EULAR) RA classification criteria (18)
were included in this study. Patients were recruited from
Diakonhjemmet Hospital (N = 28) and Martina Hansen’s
Hospital (N = 1) between 2014 and 2016 in two clinical
cohorts: (1) The Norwegian Very Early Arthritis Clinic
(NOR-VEAC) observational study (ISRCTN05526276) and
(2) The Assessing Withdrawal of Disease-Modifying Anti-
rheumatic Drugs in Rheumatoid Arthritis (ARCTIC REWIND)
trial (ClinicalTrials.gov identifier NCT01881308). The newly
diagnosed patients from NOR-VEAC (N = 11) had active
disease at inclusion and blood was drawn before treatment
with DMARD. To our knowledge, the patients did not receive
treatment with prednisolone before blood sampling. Healthy
controls recruited from the Norwegian BoneMarrow Register (N
= 9) were matched on age (±3 years), gender, smoking status
and residential area to the patients from the NOR-VEAC cohort.
The MTX-treated patients from ARCTIC REWIND (N = 18)
had symptom duration of<5 years, and the disease activity in the
patients was monitored by disease activity score 28 (DAS28) (19),
a composite score developed to measure disease activity in RA
patients. To be included in ARCTIC REWIND, a DAS28 score at
<2.6 must have been achieved for at least 12 months and stable
over the last 12 months.
Clinical Data and Statistical Comparison of
the Cohorts
At the time of blood sample withdrawal, a rheumatologist
clinically examined the patients. Available clinical data included
DAS28 score, rheumatoid factor (RF) status, ACPA status, C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR),
gender, age, smoking status andmedication (Table 1). In addition
to MTX, 6 of the 11 newly diagnosed patients and 8 of the
Frontiers in Immunology | www.frontiersin.org 2 February 2020 | Volume 11 | Article 194
Guderud et al. RA, Methylation in T-Cells
TABLE 1 | Demographic and clinical characteristics of the newly diagnosed DMARD naïve RA patient cohort, the MTX treated RA patients in remission cohort and the
healthy controls included in the study.
RA-DMARD naïve*
(N = 11)
RA-MTX treated
(N = 18)
Controls
(N = 9)
p-values
Matching criteria RA-DMARD naïve*
vs. controls
RA-MTX treated
vs. controls
Female; N (%) 8 (72.7) 15 (83.3) 7 (77.8) 0.80 0.73
Age; mean yrs N [SD] 56.1 [12.2] 49.1 [13.7] 52.4 [9.1] 0.47 0.52
Smoking; N (%) 8 (72.7) 13 (72.2) 6 (66.7) 0.77 0.77
Disease characteristics RA-DMARD naïve* vs. RA-MTX treated
Disease duration; mean yrs [SD] 0 [0.0] 2.6 [0.7] N/A <0.001
RF positive; N (%) 8 (72.7) 12 (66.7) N/A 0.73
ACPA positive; N (%) 10 (90.9) 15 (83.3) N/A 0.57
DAS28; mean [SD] 5.2 [1.7] 1.6 [0.6] N/A <0.001
CRP, mg/L; mean [SD] 21.6 [29.9] 2.2 [2.5] N/A 0.01
ESR, mm/h: mean [SD] 32 [17.9] 10.7 [7.7] N/A <0.001
MTX dosage, mg; mean [SD] 0 [0.0] 19.4 [4.6] N/A <0.001
*To the best of our knowledge, the newly diagnosed patients did not receive prednisolone before inclusion in the study.
RA, Rheumatoid arthritis; DMARD, Disease modifying antirheumatic drug; MTX, Methotrexate; Yrs, Years; SD, Standard deviation; RF, Rheumatoid factor; ACPA, Anti-citrullinated peptide
antibody; DAS28, Disease activity score in 28 joints; CRP, C-reactive protein; ESR, Erythrocyte sedimentation rate; N/A, Not applicable.
18 MTX treated patients used other medications regularly (see
Supplementary Table 1).
To statistically compare the demographic and clinical
characteristics between the patient cohorts and the healthy
controls, we used the statistical program SPSS version 25
and R version 3.3.4. Independent t-tests were used for the
continuous variables and chi-squared tests were used for the
categorical variables.
Isolation of Immune Cells and DNA
Extraction
The isolation of T cells from all samples was initiated within
30min after blood sampling. 200ml whole blood was collected
using a blood bag (Fresenius Kabi, Oslo, Norway) pre-filled with
2ml EDTA (Thermo Fisher Scientific Inc, Massachusetts, USA)
and directly diluted in 300ml PBS (PBS without MgCl, Thermo
Fisher Scientific Inc) with 1ml EDTA and 10ml fetal bovine
serum (BioNordika, Oslo, Norway). The blood-PBS solution was
transferred to 50ml SepMateTM tubes (STEMcell Technologies,
Vancouver, British Columbia, Canada) pre-filled with 14ml
Lymphoprep (Alere, Massachusetts, USA) and centrifuged
following the company’s recommendations. The peripheral
blood mononuclear cells (PBMC) enriched cell suspension was
then washed with PBS (0.4% EDTA). The CD4+ cells were
isolated using EasySepTM Human CD4+CD25+ T Cell Isolation
Kit (STEMcell Technologies) with enrichment of CD4+ cells,
followed by depletion of CD25+ cells. The CD4+CD25− cells
were separated into CD4+ memory (CD8−, CD14−, CD16−,
CD19−, CD20−, CD36−, CD56−, CD123−, TCR gamma / delta,
CD66b, glycophorinA, CD25−, CD45RO+) and CD4+ naïve
(CD8−, CD14−, CD16−, CD19−, CD20−, CD36−, CD56−,
CD123−, TCR gamma / delta, CD66b, glycophorinA, CD25−,
CD45RO−) cells [EasySepTM PE Selection Kit and CD45RO-
PE (BioLegend, San Diego; USA)]. Isolated cells were tested for
purity and viability by using BD AccuriTM C6 Cytometer (BD
Biosciences, New Jersey, USA). We used Fluorescence Minus
One (FMO) to set the gates.
DNA was isolated from CD4+ memory and CD4+ naïve
T cells using RNA/DNA/Protein Purification Plus Kit (Norgen
Biotek Corp, Ontario, Canada), and cleaned using QIAamp
DNAMicro Kit (Qiagen, Hilden, Germany). The extracted DNA
from the CD4+ naïve cells was treated with proteinase K and
RNase A (Master-Pure Complete DNA & RNA Purification kit,
Epicentre), and clean up was performed using 1.8x Agencourt
Ampure XP beads (Thermo Fisher Scientific). The extracted
DNA from CD4+ memory cells was treated with 10 mg/ml
proteinase K (Sigma-Aldrich, Missouri, USA) and cleaned with
Genomic DNA Clean & Concentrator columns (Zymo Research,
California, USA). Extracted and Proteinase K-treated DNA
from both cell types was quantified and qualified by Qubit 2.0
fluormeter dsDNA HS Assay Kit (Thermo Fisher Scientific Inc)
and NanoDrop (Model ND1000, software v3.0.0, Thermo Fisher
Scientific Inc.).
Library Preparation for Multiplexed
Reduced Representation Bisulfite
Sequencing (mRRBS)
The DNA extracted from the CD4+ naïve cells was prepped for
mRRBS on an Illumina HiSeq3000 according to the Boyle et al.
mRRBS protocol (20) using the Diagenode Premium RRBS kit
(Diagenode, Seraing, Belgium) (21). The mRRBS libraries (N =
48) were sequenced with indexes from the Diagenode Premium
RRBS kit as 50 base pair, single end reads with 20% PhiX spike in
and 6 samples per lane.
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TABLE 2 | Correlation between HiSeq machines and cell types.
Controls RA
DMARDs
naïve
RA MTX
treated
Replication
sample on
both HiSeqs
HiSeq 2500
Mean correlation
within group
0.9195 0.9450 0.9438 -
HiSeq 3000
Mean correlation
within group
0.8940 0.8707 0.9318 -
Correlation (%) 97.45 93.37 98.80 93.41
RA, Rheumatoid arthritis; DMARDs, Disease modifying antirheumatic drugs;
MTX, Methotrexate.
The CD4+ memory cells were prepped for mRRBS on
Illumina HiSeq2500 at the Institute of Clinical Molecular
Biology, Christian-Albrechts-University of Kiel, using an in-
house protocol based on Boyle et al. (20) and Gu et al. (22). The
libraries (N = 48) were sequenced as 50 base pair single end
reads with 10% PhiX spike in and 6 samples per lane. Achieved
Phred quality score was >28 in all retained reads from the
mRRBS sequencing.
One sample (technical replicate) was sequenced on both
platforms (HiSeq 2500 and HiSeq 3000) and was compared to
determine how the different sequencing platforms would impact
the results. The correlation was 0.9341 for this sample, and hence
we found the results to be comparable (Table 2).
The generated methylation data has been deposited to Gene
Expression Omnibus (accession number GSE135770).
DNA Methylation Analysis
Sequencing Alignment and Quality Control
DNAmethylation analyses were carried out using a combination
of Unix, Python, Java and R (23) with Bioconductor (v2.10)
(24). Fastq files were pre-trimmed and aligned to hg19 with
a maximum of 2 mismatches per read length using BSMAP
(25). The methratio.py script was used to calculate DNA
methylation percentage per loci. Quality control of sequencing
reads was initially performed using FastQC1. After alignment,
the alignment efficiency and specificity of the reads were
assessed using theHsMetrics andRrbsSummaryMetricswithin the
Picard software package (http://broadinstitute.github.io/picard).
To reduce a possible source of bias in the analyses, we removed
CpGs on the sex chromosomes and overlapping SNPs. RnBeads
(26) was used for further QC analyses, including manual
inspection of plots. PCA plots showed acceptable clustering,
except two outliers that were removed from further analysis (i.e.,
two controls for CD4+ memory T cells in the comparison with
MTX treated RA). A list of potentially polymorphic CpGs have
been generated using the 2011051 release of the 1,000 Genomes
project (27). To minimize the number of false positives, the data
was filtered to only include CpGs with ≥10x coverage, a group
1FASTQC A Quality Control Tool for High Throughput Sequence Data (2015).
https://www.bioinformatics.babraham.ac.uk/projects/fastqc/
size of ≥5 samples in both cases and controls and false discovery
rate (FDR) adjusted P-value ≤ 0.05. Annotation was done using
the R package AnnotatR (28) from Bioconductor.
Differential DNA Methylation
To identify differentially methylated positions (DMPs) between
the newly diagnosed RA patients and controls and between the
MTX treated RA patients and controls, we used a fitted linear
regression model using the limma package (29) implemented
in the RnBeads package (26) and the mean DNA methylation
differences between groups. In the model, we adjusted for
covariates, i.e., sex, age, smoking (never/ever), and ACPA status.
The differential DNA methylation analyses were performed
in naïve and memory CD4+ T cells, separately, to explore
differences associated with either active RA disease or MTX
treated RA in remission. QQ (quantile-quantile) plots with
lambda-values and standard errors were generated in the R
package GenABEL. The proportion of DMPs among the total
number of tested sites between the two CD4+ cell populations
was compared using chi-square tests.
Gene ontology (GO) analyses were performed based on the
results from the comparison of methylation levels in CD4+
memory cells from MTX treated RA patients and controls,
as a substantial amount of DMPs were identified using the R
package topGO, where every gene is represented by one value,
regardless of the number of sites representing a gene. For all genes
represented by <1 significant DMP, the lowest P-value among
all annotated DMPs were selected. To prioritize genes with more
than one significant DMP annotation, we took the product of all
significant DMPs into the GO analyses. Supplementary Table 2
shows the number of significant DMPs and the P-values used in
the GO analysis.
Overlap between reported RA GWAS loci and the significant
DMPs observed in our study was investigated by using a window
size of maximum ±500 kb surrounding the SNPs reported by
Yarwood et al. (30).
RESULTS
A flow chart of the study design and methodological steps is
shown in Supplementary Figure 1.
Characterization of Patient Cohorts
The demographic and clinical characteristics of the RA patients
and controls included in this study are shown in Table 1. The
control group (N = 9) did not differ from the two patient
cohorts with respect to age, gender and smoking status (P
> 0.4). When comparing the clinical parameters, the newly
diagnosed DMARD naïve RA patients had significantly higher
CRP, ESR, and DAS28 scores than the MTX treated patients (P
≤ 0.01). The mean (SD) disease duration after RA diagnosis
for the MTX treated patient cohort was 2.6 years (0.7), with an
MTX dosage at sample collection ranging from 10 to 25mg per
week with a mean of 19.4mg (Supplementary Table 1). Other
medications taken at the time of sample collection are also listed
in Supplementary Table 1.
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TABLE 3 | Summary of RRBS performance for the different subsets of T cells and cohorts.
Cell type Cohort Reads
aligned
On target
bases
Bisulfite
conversion
1x coverage
(%)
10x
coverage
(%)
Mean CpG
coverage
CD4+ naïve T cells RA-patients DMARDs naïve 20,610,227 515,258,344 98.1 52.6 25.4 12.2
CD4+ naïve T cells RA-patients MTX treated 21,193,235 513,852,255 99.3 52.5 25.1 11.7
CD4+ naïve T cells Healthy controls 21,045,056 489,122,790 99.4 52.5 24.5 12.1
CD4+ memory T cells RA-patients DMARDs naïve 13,977,649 359,190,451 99.7 45.8 18.5 9.7
CD4+ memory T cells RA-patients MTX treated 18,677,449 437,185,779 99.7 44.0 19.6 12.0
CD4+ memory T cells Healthy controls 16,545,688 371,925,046 99.7 45.3 18.2 10.5
CD4+ naïve T cells were sequenced on HiSeq 3000, while CD4+ memory T cells were sequenced on HiSeq 2500 (see section materials and methods). Data have been generated
using HS metrics and RRBS metrics from Picard tools. Median values across samples are given.
RA, Rheumatoid arthritis; DMARDS, Disease modifying antirheumatic drugs; MTX, Methotrexate.
Data Generation and Quality Assessment
Flow cytometry showed that the median purity of CD4+ memory
T cells (CD4+CD45RO+) was 95% (range 79–99%), whereas for
CD4+ naïve T cells (CD4+CD45RA+) the median purity was
86% (range 54–98%) (Supplementary Figure 2). The median
purity did not deviate between the three cohorts. PCA plots based
on the individual methylation profiles showed that the samples
with lower cell type purity did not cluster differently than those
with high cell type purity.
The bisulfite conversion rate was 99.7% across all cohorts for
CD4+ memory cells, and ranged from 98.1–99.4% in the CD4+
naïve cell samples (Table 3). The numbers of aligned RRBS reads
were >13.9 million for each subset of samples (divided by cohort
and cell type), and the mean CpG coverage was >9.5 per sample
(Table 3). The on target base count were >350 million across
the samples and cohorts, and the mean 10x coverage ranged
from 18.2–25.4%.
Both RA Cohorts Displayed More DNA
Methylation Differences in Memory T Cells
Than in Naïve T Cells
We systematically compared DNA methylation levels between
RA patients (both newly diagnosed DMARD naïve patients
and MTX treated patients) and matched healthy controls in
memory and naïve CD4+ T cells. QQ-plots of the P-values
for all four comparisons were distributed within the normality
area (Figure 1). The global mean DNA methylation across CpGs
throughout the genome was 72–73% for CD4+ naïve T cells and
61–62% for CD4+ memory T cells across all datasets (Table 4).
Analyses of newly diagnosed, DMARD naïve RA patients
identified 51 significant DMPs (of 933 808 tested sites) in CD4+
memory T cells and three significant DMPs (of 1 389 561 tested
sites) in CD4+ naïve T cells (Table 5). Hence, significantly (P= 2
× 10−9) more of the CpG sites were differentially methylated in
CD4+ memory T cells (0.5%) than in CD4+ naïve T cells (0.02%)
from the newly diagnosed DMARD naïve RA patients.
TheMTX treated RA patients in remission showed differential
DNA methylation at 853 CpGs in CD4+ memory T cells,
and at 16 CpGs in CD4+ naïve T cells compared to healthy
controls (Table 5). Again, there was a significant difference in the
proportion of DMPs (P= 2x10−68); 853DMPs of 1 035 857 tested
sites in CD4+ memory T cells (8.2%) vs. 16 DMPs of 1 447 202
tested sites in CD4+ naïve T cells (0.11%) (Table 5).
As stated above, the MTX treated RA patients showed
substantially more DMPs than the newly diagnosed DMARD
naïve patients. However, it should be noted that the MTX treated
RA patient cohort is larger and has more statistical power (18
vs. 11 patients). To address the effect of power between the
two cohorts, we calculated how many of the DMPs in the MTX
treated RA patients were significant before FDR correction in the
less powerful cohort of newly diagnosed RA patients and found
92% of the DMPs in CD4+ memory T cells had an uncorrected P
< 0.05. In contrast, among all tested CpGs, only 4.2% showed
an uncorrected significant P-value. Hence, an enrichment of
sites showing a trend toward association was seen among the
DMPs already found in the MTX treated patients indicating
that power is a likely cause of the vast differences in number of
significant sites.
Nevertheless, 11 of the 20 most significant DMPs (P
≤0.0003), in any of the comparisons, were detected in newly
diagnosed patients (CD4+ memory T cells), including the
transcription factor STAT5, which is found to be an essential
regulator of lymphoid development and peripheral tolerance (31)
(Supplementary Table 3).
The distribution of DMPs across chromosomes identified in
these analyses is shown in Figure 2. None of the significant
(FDR corrected) DMPs in the newly diagnosed RA patients were
significant in the MTX treated RA patients. Hence, we did not,
with statistical significance, identified any RA associated DMPs
not influenced by disease state.
DMPs in CD4+ Memory T Cells Showed
Increased Methylation in DMARD Naïve
Patients and Decreased Methylation in
MTX Treated Patients
In newly diagnosed DMARD naïve RA patients, the identified
DMPs showed increased DNA methylation, 100% of the DMPs
in CD4+ naïve T cells and 64% of the DMPs in CD4+ memory
T cells. In MTX treated patients in remission, 80% of the
DMPs detected in CD4+ memory T cells displayed decreased
methylation, whereas in CD4+ naïve T cells the proportions of
DMPs associated with increased and decreased DNAmethylation
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FIGURE 1 | QQ-plots and lambda values of the association between RA patients and controls for all tested methylation sites in the different cohorts and cell types.
RA, Rheumatoid arthritis; MTX, Methotrexate; SE, Standard error.
were equivalent. We also found that 90 of the DMPs were in
close proximity (within 100 kB) to another significant DMP.
Table 5 shows the top 40 genes annotated to the most significant
DMPs; several annotations were possible for each DMP and
the majority of the DMPs were annotated to intronic regions
(Supplementary Table 3).
The significant DMPs did not overlap between either
CD4+ T cell subset or patient cohort (Supplementary Table 3).
However, when comparing genes associated and annotated to
the DMPs, two genes emerged; GRID2IP showed decreased DNA
methylation in CD4+ memory T cells from both RA cohorts,
and PLEKHM1P1 showed decreased DNA methylation in both
memory and naïve CD4+ T cells from MTX treated RA patients
in remission.
DMPs Previously Associated With RA
Amongst genes previously reported to have been associated
with differential DNA methylation in T cells from RA patients,
two genes were replicated in our study; GALNT9 and DUSP22
TABLE 4 | Mean global methylation combining all CpG sites from each data set.
Cell subset Data sets Controls RA
patients
CD4+ memory
T cells
MTX treated RA patients vs.
controls
0.6224 0.6216
Newly diagnosed RA patients
vs. controls
0.6083 0.6052
CD4+ naïve
T cells
MTX treated RA patients vs.
controls
0.7171 0.7171
Newly diagnosed RA patients
vs. controls
0.7204 0.7279
The sites are filtered to include CpGs with ≥10x coverage and a group size of ≥5 in both
cases and controls.
RA, Rheumatoid arthritis; MTX, Methotrexate.
(12, 14, 15). GALNT9 was significantly less methylated in our
MTX treated RA patients compared to controls, but only in
CD4+ memory T cells. The significant DMPs in our dataset
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TABLE 5 | Filtration criteria for identification of differentially methylated CpG sites in the two RA patient cohorts compared to the healthy controls.
Cell type Cohort vs.
controls
Number of
sites
Mean
coverage
Significant
sites
Significant
genes
Gene names
Increased methylation in
RA patients
Decreased methylation in
RA patients
CD4+ naïve
T cells
Newly diagnosed
DMARD naïve RA
patients
1 538 979 1 389 561 3 2 SPTA1, MCC -
CD4+ naïve
T cells
MTX treated RA
patients
1 657 054 1 447 202 16 11 SNX11, PLA1A, ZNF732,
EPS15L1, STON1-GTF2A1L,
STON1,
CACTIN, LOC100134317,
RGPD3, PLEKHM1P1,
SMYD3
CD4+ memory
T cells
Newly diagnosed
DMARD naïve RA
patients
984 219 933 808 51 37 YPEL1, NELFA, CTNNA2,
PARD3B, ZFP14, PHTF2,
IL4I1, PGBD4, EMC7,
PCSK7, RNF214, PLEKHD1,
POLE2, KLHDC1, NEMF,
RNF180, MIR129-2,
SAMD10, PRPF6, REST,
SUDS3, TRANK1, AP4E1,
TEAD4, ZFP3, POM121C
FAM63B, MAPK8IP3,
STAT5A, ZNF668, ZNF646,
TMED10, CES2, GRID2IP,
PLEKHA2, IQGAP3, GGCX,
CD4+ memory
T cells
MTX treated RA
patients
1 067 343 1 035 857 853 542 C7orf77, DENND5B,
YWHAEP7, TMC5, SLCO2B1,
SOX9
TTC37, MOXD1, TMEM129,
TACC3, HIST2H3C, ISPD,
LINC00862, DPP6, RORA,
RNFT2, CAMKK1, TBXAS1,
HIPK2, GNA15, DIAPH3,
KCNJ6, LHFPL3, TRAF2,
COL4A4, GALNT9, CYBA,
MAP6, TBC1D3, ITPK1,
PALM, TTC39B, EVI5L, MN1,
S100A1, S100A13, PTPRO,
FNDC3B, DLG2, UBIAD1
The number, names and methylation status of top 40 significant genes are also included.
RA, Rheumatoid arthritis; DMARD, Disease modifying antirheumatic drugs; MTX, Methotrexate; p.adj.fdr. p-value adjusted for false discovery rate.
FIGURE 2 | Modified Manhattan plots displaying mean change in methylation per site at their chromosomal position. Differentially methylated sites (FDR-adjusted p <
0.05) associated with positive changes in DNA methylation in patients relative to controls are marked in green; negative changes are marked in red. RA, Rheumatoid
arthritis; MTX, Methotrexate. (A) CD4+ naïve T cells: Newly diagnosed RA patients vs. controls. (B) CD4+ memory T cells: Newly diagnosed RA patients vs. controls.
(C) CD4+ naïve T cells: MTX treated RA patients vs. controls. (D) CD4+ memory T cells: MTX treated RA patients vs. controls.
were located in intron 1 which is consistent with the study by
Glossop et al. (12). However, the intron 1 DMPs were only
interrogated in CD4+ memory T cells from MTX treated RA
patients. Other studies have reported various sites in intron
5 (Figure 3). The intron 5 region covering the previously
reported DMPs was covered in our cohorts. Unfortunately, the
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other cohorts in our study showed poor coverage upstream
of intron 5 and were therefore excluded from analyses.
DUSP22 was covered by CpGs across the gene in our samples,
including the sites previously reported (Figure 4). However,
no significant DMPs were found in this region in any of our
data sets.
Of note, while the present study is based on RRBS, previous
studies have analyzed DNA methylation using the Meth450K.
Thesemethods are not directly comparable and<2% of the CpGs
tested in our RRBS study are present on the Meth450K (Table 6).
Therefore, only 13 of the 923 significant DMPs identified in
our study have been analyzed in former studies based on
Meth450K data.
RA Associated DMPs Are in Close
Proximity to Genetic RA Risk Loci
We next investigated whether any of the significant DMPs
overlapped with RA susceptibility loci (30) (±500 kb from the
lead SNP) in CD4+ memory T cells (Supplementary Table 4). 32
of the 101 tested RA risk SNPs were within 500 kb of at least one
DMP. Two SNPs (rs72634030-C1QBP and rs5754217-UBE2L3)
were located near DMPs detected in CD4+ memory T cells from
newly diagnosed DMARD naïve RA patients. No overlap was
detected between RA SNPs and the 19 DMPs detected in CD4+
naïve T cells.
The CD4+ memory T cells from MTX treated RA patients
displayed differential DNA methylation at several CpGs within
the regions surrounding the RA risk SNPs. When selecting an
equal number of CpGs randomly among our tested sites, we
generally observed a lower number of overlapping RA SNPs,
however, the association between DMPs and RA risk loci did not
reach statistical significance (P = 0.1 after 1000 permutations).
Interestingly, several of these RA risk SNPs have been annotated
as eQTLs located in H3K4me3 peaks in memory T cells (i.e.,
FCRL3, CD83, ANKRD55, IRF5, BLK, IKZF3, TRAF1, and
IFNGR2). The distance between the lead risk SNP and the DMPs
identified in our study showed substantial variation (from 4 to
434 kb). For TRAF1, the distance between the risk SNP and the
DMP was only 4 kb, and the DMP was located within an intron
of the TRAF1 gene. This DMP was completely unmethylated in
CD4+ memory T cells from controls, but showed detectable, but
low DNAmethylation levels in CD4+ memory T cells fromMTX
treated RA patients.
The gene closest to the risk SNP was often not the same as
the gene closest to the DMPs within the overlapping genetic
and epigenetic RA associated regions. However, both the DMP
and risk SNP pointed toward the same gene for PTPN2, IRF8,
UBASH3A, TRAF1, CD83, and FCGR2A. In addition, the RA risk
SNP (rs1893592) is located in intron 1 of UBASH3A, while the
two DMPs detected in our study mapped to intron 4 and 14
of UBASH3A (Supplementary Table 4). The UBASH3A DMPs
were found to show reduced mean methylation in RA patients in
CD4+ memory T cells and this difference was significant in the
MTX-treated RA patients after FDR correction. The same trend
was seen in the newly diagnosed DMARD naïve RA patients,
but was not significant after correction for multiple testing
(Figure 5).
Gene Ontology
The CpGs tested in this study were annotated to a total of 20,449
genes, the number of CpGs per gene ranged from 1 to 1257,
and the majority of the genes were covered with ≥5 CpG sites
(Supplementary Table 2).
We performed GO analyses on the significant DMPs
in CD4+ memory T cells from MTX treated patients in
remission compared to controls (Table 7). The most significantly
enriched GO term was skeletal system morphogenesis, which
includes the terms cartilage condensation of mesenchymal cells
that have been committed to differentiate into chondrocytes
(GO:0001502) and bone trabecula formation (GO:0060346).
Other significantly enriched GO terms included chromatin
remodeling, negative regulation of response to endoplasmic
reticulum stress, regulation of transcription involved in cell fate
commitment, animal organ morphogenesis and blood vessel
development (Table 7).
Comparisons of Newly Diagnosed and
MTX Treated RA Patients
Finally, we performed a pilot analysis, where we selected eleven of
the MTX treated RA patients to best match our newly diagnosed
RA patients according to age, gender and smoking status, and
compared their methylation profiles in a paired test. We found
360 DMPs in CD4+ naïve T cells and 86 DMPs in CD4+ memory
T cells (Supplementary Table 5). None of the genes annotated
for these DMPs overlapped with genes associated with DMPs
found when comparing newly diagnosed patients with controls.
However, eight genes had also been detected to have DMPs when
comparing MTX treated patients to controls, i.e., SMYD3 in
CD4+ naïve T cells andCABLES1, B4GALNT3, EXOC6B,RASA4,
MIR148A, ADCY1, MAD1L1. The methylation of these genes
is therefore likely to be caused by MTX treatment and long
term RA.
DISCUSSION
Our epigenome-wide association study showed that CD4+ T
cells displayed more DNA methylation differences in CD4+
memory T cells than in CD4+ naïve T cells, when comparing
RA patients with controls. This was observed in both newly
diagnosed DMARD naïve patients and MTX treated patients in
remission, but the DMPs did not overlap between the two states
of RA disease. However, due to differences in power for the two
cohorts, we cannot exclude that some DMPs overlap between
these two RA disease states.
Overall, we observed a higher global mean methylation in
CD4+ naïve T cells than in CD4+ memory T cells, which is
in accordance with observations on a whole genome-wide level,
where a loss of DNA methylation occurs upon transition from
naïve to memory CD4+ T cells (16).
Our study replicated the finding of DMPs in the gene
GALNT9, which previously has been reported in CD4+ T cells
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FIGURE 3 | Methylation values related to the gene GALNT9. (A) RA-MTX treated patients vs. controls, CD4+ memory T cells. (B) RA-MTX treated patients vs.
controls, CD4+ naive T cells. (C) Newly diagnosed RA patients vs. controls, CD4+ memory T cells. (D) Newly diagnosed RA patients vs. controls, CD4+ naive T cells.
Teal, RA patients; Red, Controls. Gene track (bottom) showing exons and introns in GALNT9, with corresponding individual methylation (top) showing distribution and
methylation ratio of the DMPs. Smoothed lines show an overall methylation trend between the two time-points. RA, Rheumatoid arthritis; MTX, Methotrexate; DMPs,
Differentially methylated positions.
(12, 14). DMPs in this gene consistently show decreased DNA
methylation in RA patients across all studies, which strengthens
the evidence that this gene might play a part in the pathogenesis
of RA.
We did not replicate the DMPs in the other gene repeatedly
reported in RA methylation studies in T and B cells, i.e., DUSP22
(12, 13). However, it should be emphasized that the set of CpG
sites investigated by our study using RRBS had very little overlap
with the CpG sites interrogated by the Meth450K array used
in previous studies. Even though we tested more than twice
as many sites, only 20 000 of the 1 million sites measured in
our study were present on the Meth450K. Such small overlap
between CpGs interrogated by RRBS and Meth450K has been
reported previously (32). Among our significant DMPs, only 13
were present on the Meth450K. Since we investigated a different
set of CpG sites in our study, we have limited ability to compare
our results to those previously published. To the best of our
knowledge our study is the first to use RRBS to study methylation
differences in specific T cell populations from RA patients. As
such, it provides novel insight into methylation events in new
genomic regions.
Previous studies in RA have generally been performed on
bulk T cells or CD4+ T cells (12–14, 33). However, epigenomic
profiling of human CD3+CD4+CD25low T cell subsets from
healthy individuals show distinct DNA methylation patterns per
se between CD4+ naïve and memory T cells (16). One previous
study, by Rhead et al. investigated DNA methylation differences
in cell subpopulations from RA patients (15). In contrast
to our findings, they reported more sites to be differentially
methylated between RA patients and controls in CD4+ naïve
T cells than in CD4+ memory T cells. This discrepancy may
be caused by different methodologies such as differences in cell
selection techniques (magnetic beads vs. FACS), CD25 depletion
(only carried out in our study), and differences in sequencing
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FIGURE 4 | Methylation values related to the gene DUSP22. (A) RA-MTX treated patients vs. controls, CD4+ memory T cells. (B) RA-MTX treated patients vs.
controls, CD4+ naive T cells. (C) Newly diagnosed RA patients vs. controls, CD4+ memory T cells. (D) Newly diagnosed RA patients vs. controls, CD4+ naive T cells.
Teal, RA patients; Red, Controls. Gene track (bottom) showing exons and introns in DUSP22, with corresponding individual methylation (top) showing distribution and
methylation ratio of the DMPs. Smoothed lines show an overall methylation trend between the two time-points. RA, Rheumatoid arthritis; MTX, Methotrexate; DMPs,
Differentially methylated positions.
technology including CpG positions and coverage (i.e., RRBS
vs. Meth450k). In addition, differences in patient cohorts
may also account for some of the differences in the results.
One of the strengths of our study was the well-characterized
and homogenous patient cohorts, where disease activity and
treatment was known. Patients included in the study by Rhead
et al., had longer disease duration, were all female and with no
information regarding treatment and disease activity.
Previous studies indicate that MTX treatment reverses
methylation differences in PBMC and T cells (33, 34), and that
MTX treated patients have global DNA methylation levels more
similar to controls than to patients with active disease. In our
study, MTX treated RA patients in remission displayed more
methylation differences than newly diagnosed DMARD naïve RA
patients with active disease. Whether and to what extent this
is a true difference is difficult to evaluate, as the sample size of
our MTX treated RA patient cohort exceeded that of the newly
diagnosed patients (18 vs. 11), and hence impact the statistical
power. Interestingly, the UBASH3A gene showed the same DNA
methylation levels and differences for CD4+ memory T cells in
both MTX treated and newly diagnosed patients compared to
controls, but the difference was only significant after correction
in the larger cohort of MTX treated patients. Importantly, 785
(92%) of the DMPs significant after FDR correction of P-values in
MTX treated patients had a significant P-value (P <0.05) before
correction in the newly diagnosed patients. This supports the
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TABLE 6 | Overlap between our tested methylation sites after RRBS and sites present on different arrays (Meth450K, EPIC, and 27K) after filtering the reads (coverage
per site >10 and observed in ≥5 individuals).
Sites also present on Meth450 K Sites also present on EPIC array Sites also present on 27 K
Total sites
tested in our
study
Among our
tested sites
Among our
significant
DMPs
Among our
tested sites
Among our
significant
DMPs
Among our
tested sites
Among our
significant
DMPs
Newly diagnosed RA patients vs.
controls (CD4+ naïve T cells)
1 389 561 23 659 0 27 263 0 930 0
MTX treated RA patients vs.
controls (CD4+ naïve T cells)
1 447 202 24 823 0 28 722 0 1000 0
Newly diagnosed RA patients vs.
controls (CD4+ memory T cells)
933 808 18 321 0 21 530 0 1004 1
MTX treated RA patients vs.
controls (CD4+ memory T cells)
1 035 857 19 157 13 22 736 13 1047 0
RA, Rheumatoid arthritis; RRBS, Reduced representation bisulfite sequencing; DMP, Differentially methylated position; MTX, Methotrexate.
FIGURE 5 | Box plots showing the methylation ratio in two different DMPs in the gene UBASH3A in controls (green) and in RA patients (pink) in either CD4+ memory
or naïve T cells. RA, Rheumatoid arthritis; MTX, Methotrexate; Pc, Corrected P-value; Pnc, Not corrected P-value.
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TABLE 7 | Gene ontology displaying the top 10 best ranked GO terms in CD4+
memory T cells from MTX treated patients in remission.
GO.ID Term Annotated Significant Classic
fisher
GO:0048705 Skeletal system
morphogenesis
113 10 0.0012
GO:1903573 Negative regulation of
response to endoplasmic
reticulum stress
19 4 0.0017
GO:0099072 Regulation of postsynaptic
membrane neurotransmitter
receptor levels
32 5 0.0018
GO:0060850 Regulation of transcription
involved in cell fate
commitment
10 3 0.0023
GO:0009887 Animal organ morphogenesis 524 26 0.003
GO:0070534 Protein K63-linked
ubiquitination
23 4 0.0036
GO:0001568 Blood vessel development 335 18 0.0061
GO:0043552 Positive regulation of
phosphatidylinositol 3-kinase
activity
14 3 0.0064
GO:0006338 Chromatin remodeling 79 7 0.0066
GO:0007417 Central nervous system
development
450 22 0.0075
notion that differences in statistical power may in part explain
the differences between the RA cohorts.
We found that most of the differentially methylated regions
were located outside promoters, in intronic regions. The
biological function of intragenic DNA methylation is less clear,
but it may regulate usage of alternative promoters and alternative
splicing (35). In gene bodies, unlike promoters, there is not
always a negative correlation between DNA methylation and
transcription, in some tissues, active genes are more methylated
than repressed genes. Overall, intragenic CpGs appear to be
functionally important and play a role in fine tuning of
gene regulation.
One third of our DMPs were located in the vicinity of
genetic risk loci for RA (±500 kb away from lead SNP).
Only 6 of the 38 genes overlapping or being closest to our
DMPs, were consistent with genes reported from GWAS hits.
However, few GWAS regions in autoimmune diseases have yet
converged on a causal gene. An exception isUBASH3A, encoding
ubiquitin-associated and SH3 domain containing protein A,
which functions as a negative regulator of NF-kB signaling in
T cells on stimulation of the antigen T cell receptor (36). Non-
coding susceptibility alleles within UBASH3A are associated with
several autoimmune diseases, including type 1 diabetes and RA,
and are also associated with increased transcription, thereby
leading to reduced transcription of interleukin-2 (IL2) in effector
T cells (36). An association study by Liu et al. identified one
SNP (rs1893592) in UBASH3A that was significantly related to
DAS28, CRP level and bone erosion in RA patients (37). In line
with this, we found decreased DNA methylation of two DMPs
within UBASH3A in CD4+ memory T cells in MTX treated RA
patients compared to controls, presumably leading to increased
expression of UBASH3A. Interestingly, the autoimmune risk
variant at rs1893592 in UBASH3A is associated with decreased
lymphocyte percentage in the UK biobank cohort (38). Future
methQTL analysis in a larger dataset, may address whether
risk genotypes at the RA associated SNPs are correlated with
methylation levels at these loci.
The most important limitation of our study is the small
number of patients, which limits the statistical power. To
compensate for this, we focused on minimizing the noise
by using homogenous datasets (i.e., using two homogenous
RA populations and investigating two distinct CD4+ T cell
subsets). Unfortunately, two different laboratory procedures
and sequencing instruments were used, one for each cell type.
However, the sample that was included on both platforms showed
93.4% correlation.
CONCLUSION
In conclusion, by focusing on specific T cell populations highly
relevant for RA (CD4+ naïve and memory T cells) from two
phenotypically distinct and homogeneous RA cohorts using
an epigenome wide RRBS sequencing approach, we discovered
intrinsic DNA methylation differences, including confirmation
of decreased DNA methylation in CpGs within GALNT9 in RA
patients. One third of the known RA risk SNPs were located in
the vicinity of our DMPs, and one of the most robust findings was
for UBASH3A. Nevertheless, larger studies of homogenous RA
patients and controls comprising bisulfite sequencing of relevant
immune cell subsets are necessary to further establish the changes
in DNA methylation that play a part in RA pathogenesis, drug
response and disease development before the putative role of
epigenetic factors can be assessed in a clinical setting.
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